The National Institutes of Health (NIH) has awarded multi-year, multi-million dollar grants to The Case Clinical Trials Unit centered at University Hospitals Case Medical Center (UHCMC), for expanded research options in HIV treatment development and pioneering advances of the Microbicides Trials Network.
Two papers in the February 24 issue of The Lancet provide detailed analyses of two NIAID-funded clinical trials of adult male circumcision in Kenya and Uganda. In the trial of 2,784 HIV-negative men in Kisumu, Kenya, the investigators found the rate of HIV acquisition in circumcised men to be 53 percent lower than in uncircumcised men. Investigators in the trial of 4,996 HIV-negative men in Rakai, Uganda, report that HIV acquisition was reduced by 51 percent in circumcised men.
African scientists will soon begin training at Emory University as part of a unique partnership between Emory and the Republic of South Africa. The South Africa Drug Discovery Training Program will address the rising dangers of diseases that unduly affect developing countries.
Experts call for HSV control measures, including vaccine, to rank high on international HIV prevention and research agenda as exciting trial findings are published.
After the death of a loved one from natural causes, the normal responses from most people are acceptance and yearning for the deceased, according to a new study in the February 21 issue of JAMA that is an empirical examination of the stage theory of grief.
The International AIDS Vaccine Initiative (IAVI) issued this statement today following an announcement made by the Canadian government and the Bill & Melinda Gates Foundation to pledge up to CAD$139 million for the creation of a Canadian HIV Vaccine Initiative (CHVI).
Medically performed circumcision significantly reduces a man?s risk of acquiring HIV?the virus that causes AIDS?through heterosexual intercourse, according to 2 studies.
Bioengineers and public health researchers at Harvard University have developed a novel spraying method for delivering the most common tuberculosis (TB) vaccine, providing a new low-cost and scaleable technique that offers needle-free delivery and greater stability at room temperature than existing methods.
Merck & Co., Inc. announced that it has begun to file registrations for ATRIPLA? (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), a once-daily, single tablet regimen for the treatment of HIV-1 infection in adults, with health authorities in those developing countries around the world where many HIV-positive people live.
A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows.